Summary

Oncolytic Virus Immunotherapy Market – Scope of Report
TMR’s report on the global oncolytic virus immunotherapy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global oncolytic virus immunotherapy market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global oncolytic virus immunotherapy market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the oncolytic virus immunotherapy market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global oncolytic virus immunotherapy market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global oncolytic virus immunotherapy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global oncolytic virus immunotherapy market.

The report delves into the competitive landscape of the global oncolytic virus immunotherapy market. Key players operating in the global oncolytic virus immunotherapy market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global oncolytic virus immunotherapy market profiled in this report.

Key Questions Answered in Global oncolytic virus immunotherapy Market Report
• What is the sales/revenue generated by oncolytic virus immunotherapy across all regions during the forecast period?
• What are the opportunities in the global oncolytic virus immunotherapy market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Oncolytic Virus Immunotherapy Market – Research Objectives and Research Approach
The comprehensive report on the global oncolytic virus immunotherapy market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global oncolytic virus immunotherapy market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global oncolytic virus immunotherapy market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Oncolytic Virus Immunotherapy Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2017-2031
6.3.1. Herpes Simplex Virus
6.3.2. Vaccinia Virus
6.3.3. Adenovirus
6.3.4. Reovirus
6.3.5. Others
6.4. Market Attractiveness Analysis, by Type
7. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2017-2031
7.3.1. Intratumoral
7.3.2. Intravenous
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Application, 2017-2031
8.3.1. Melanoma
8.3.2. Non-small Cell Lung Cancer (NSCLC)
8.3.3. Pancreatic Cancer
8.3.4. Breast Cancer
8.3.5. Others
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Oncolytic Virus Immunotherapy Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Type, 2017-2031
10.3.1. Herpes Simplex Virus
10.3.2. Vaccinia Virus
10.3.3. Adenovirus
10.3.4. Reovirus
10.3.5. Others
10.4. Market Value Forecast, by Route of Administration, 2017-2031
10.4.1. Intratumoral
10.4.2. Intravenous
10.5. Market Value Forecast, by Application, 2017-2031
10.5.1. Melanoma
10.5.2. Non-small Cell Lung Cancer (NSCLC)
10.5.3. Pancreatic Cancer
10.5.4. Breast Cancer
10.5.5. Others
10.6. Market Value Forecast, by Country, 2017-2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Type
10.7.2. By Route of Administration
10.7.3. By Application
10.7.4. By Country
11. Europe Oncolytic Virus Immunotherapy Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Type, 2017-2031
11.3.1. Herpes Simplex Virus
11.3.2. Vaccinia Virus
11.3.3. Adenovirus
11.3.4. Reovirus
11.3.5. Others
11.4. Market Value Forecast, by Route of Administration, 2017-2031
11.4.1. Intratumoral
11.4.2. Intravenous
11.5. Market Value Forecast, by Application, 2017-2031
11.5.1. Melanoma
11.5.2. Non-small Cell Lung Cancer (NSCLC)
11.5.3. Pancreatic Cancer
11.5.4. Breast Cancer
11.5.5. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Type
11.7.2. By Route of Administration
11.7.3. By Application
11.7.4. By Country/Sub-region
12. Asia Pacific Oncolytic Virus Immunotherapy Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Type, 2017-2031
12.3.1. Herpes Simplex Virus
12.3.2. Vaccinia Virus
12.3.3. Adenovirus
12.3.4. Reovirus
12.3.5. Others
12.4. Market Value Forecast, by Route of Administration, 2017-2031
12.4.1. Intratumoral
12.4.2. Intravenous
12.5. Market Value Forecast, by Application, 2017-2031
12.5.1. Melanoma
12.5.2. Non-small Cell Lung Cancer (NSCLC)
12.5.3. Pancreatic Cancer
12.5.4. Breast Cancer
12.5.5. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Type
12.7.2. By Route of Administration
12.7.3. By Application
12.7.4. By Country/Sub-region
13. Latin America Oncolytic Virus Immunotherapy Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Type, 2017-2031
13.3.1. Herpes Simplex Virus
13.3.2. Vaccinia Virus
13.3.3. Adenovirus
13.3.4. Reovirus
13.3.5. Others
13.4. Market Value Forecast, by Route of Administration, 2017-2031
13.4.1. Intratumoral
13.4.2. Intravenous
13.5. Market Value Forecast, by Application, 2017-2031
13.5.1. Melanoma
13.5.2. Non-small Cell Lung Cancer (NSCLC)
13.5.3. Pancreatic Cancer
13.5.4. Breast Cancer
13.5.5. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Type
13.7.2. By Route of Administration
13.7.3. By Application
13.7.4. By Country/Sub-region
14. Middle East & Africa Oncolytic Virus Immunotherapy Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Type, 2017-2031
14.3.1. Herpes Simplex Virus
14.3.2. Vaccinia Virus
14.3.3. Adenovirus
14.3.4. Reovirus
14.3.5. Others
14.4. Market Value Forecast, by Route of Administration, 2017-2031
14.4.1. Intratumoral
14.4.2. Intravenous
14.5. Market Value Forecast, by Application, 2017-2031
14.5.1. Melanoma
14.5.2. Non-small Cell Lung Cancer (NSCLC)
14.5.3. Pancreatic Cancer
14.5.4. Breast Cancer
14.5.5. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Type
14.7.2. By Route of Administration
14.7.3. By Application
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Amgen Inc.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Merck & Co., Inc. (Viralytics Limited)
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Shanghai Sunway Biotech Co., Ltd.
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. TILT Biotherapeutics
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Oncorus, Inc.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Replimune Group, Inc.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Oncolys Biopharma, Inc.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Sorrento Therapeutics, Inc.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Oncolytics Biotech, Inc.
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. SillaJen, Inc.
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview